Across TCGA pan-cancer cohorts, CREG2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CREG2 data layer compared with 22 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CREG2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CREG2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
LUAD and UCEC are the cancer types where CREG2 Mutation most reproducibly stratifies survival.